PMID- 11435293
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 98
IP  - 2
DP  - 2001 Jul 15
TI  - Survival of transfused donor white blood cells in HIV-infected recipients.
PG  - 272-9
AB  - The appearance and expansion of donor white blood cells in a recipient after 
      transfusion has many potential biologic ramifications. Although patients with HIV 
      infection are ostensibly at high risk for microchimerism, transfusion-associated 
      graft-versus-host disease (TA-GVHD) is rare. The purpose of this study was to 
      search for sustained microchimerism in such patients. Blood samples were 
      collected from 93 HIV-infected women (a subset from the Viral Activation 
      Transfusion Study, an NHLBI multicenter randomized trial comparing leukoreduced 
      versus unmodified red blood cell [RBC] transfusions) before and after 
      transfusions from male donors. Donor lymphocytes were detected in posttransfusion 
      specimens using a quantitative Y-chromosome-specific polymerase chain reaction 
      (PCR) assay, and donor-specific human leukocyte antigen (HLA) alleles were 
      identified with allele-specific PCR primers and probes. Five of 47 subjects 
      randomized to receive nonleukoreduced RBCs had detectable male lymphocytes 1 to 2 
      weeks after transfusion, but no subject had detectable male cells more than 4 
      weeks after a transfusion. In 4 subjects studied, donor-specific HLA haplotypes 
      were detected in posttransfusion specimens, consistent with one or more donors' 
      cells. None of 46 subjects randomized to receive leukoreduced RBCs had detectable 
      male lymphocytes in the month after transfusion. Development of sustained 
      microchimerism after transfusion in HIV-infected patients is rare; HIV-infected 
      patients do not appear to be at risk for TA-GVHD.
FAU - Kruskall, M S
AU  - Kruskall MS
AD  - Departments of Pathology and Medicine, Beth Israel Deaconess Medical Center, 
      Harvard Medical School, Boston, MA 02215, USA.
FAU - Lee, T H
AU  - Lee TH
FAU - Assmann, S F
AU  - Assmann SF
FAU - Laycock, M
AU  - Laycock M
FAU - Kalish, L A
AU  - Kalish LA
FAU - Lederman, M M
AU  - Lederman MM
FAU - Busch, M P
AU  - Busch MP
CN  - Viral Activation Transfusion Study Group
LA  - eng
GR  - N01-HB-57115/HB/NHLBI NIH HHS/United States
GR  - N01-HB-57126/HB/NHLBI NIH HHS/United States
GR  - N01-HB-57127/HB/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Blood Component Removal
MH  - Blood Donors
MH  - Cell Separation
MH  - *Cell Survival
MH  - DNA/blood
MH  - Double-Blind Method
MH  - *Erythrocyte Transfusion
MH  - Female
MH  - HIV Infections/blood/*therapy
MH  - Humans
MH  - *Leukocytes
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Transplantation Chimera
MH  - Y Chromosome
EDAT- 2001/07/04 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/07/04 10:00
PHST- 2001/07/04 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/07/04 10:00 [entrez]
AID - S0006-4971(20)46845-4 [pii]
AID - 10.1182/blood.v98.2.272 [doi]
PST - ppublish
SO  - Blood. 2001 Jul 15;98(2):272-9. doi: 10.1182/blood.v98.2.272.